Viking Therapeutics to Participate in Upcoming Investor Conferences

June 10, 2021 4:05 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

SAN DIEGO, Calif., June 10, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences. 

Details of the company's participation are as follows:

  • SVB Leerink CybeRx Series: Liver Disease DayDetails: Viking management will participate in 1-on-1 meetingsConference Date: June 17, 2021 Format: Virtual Conference   
  • Raymond James Human Health Innovations ConferenceDetails: Viking management will participate in a panel discussion and 1-on-1 meetingsConference dates: June 21-23, 2021Panel Discussion Timing: 12:00 p.m. Eastern on Wednesday, June 23, 2021Format: Virtual conference

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.  Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.  In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.  The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial.  The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301309290.html

SOURCE Viking Therapeutics, Inc.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

PRNewswire, Press Releases

Related Entities

Raymond James, Twitter